SCHEMBL3394777

SCHEMBL3394777

COc1ccc2c(c1)CCN(C1CCC(c3ccccc3)CC1)CC2O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 7/20 0.74
GRIN1 Q05586 6/20 0.74
DRD1 P21728 2/20 0.52
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD5 P21918 1/20 0.49
DRD3 P35462 1/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
ORAI1 Q96D31 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394780 1.00 GRIN2B (0.74) GRIN2BGRIN1DRD1KDM4EALDH1A1
SCHEMBL3396820 1.00 GRIN2B (0.74) GRIN2BGRIN1DRD1KDM4EALDH1A1
SCHEMBL18587456 1.00 GRIN2B (0.74) GRIN2BGRIN1DRD1KDM4EALDH1A1
SCHEMBL3390701 0.85 GRIN1 (1.00) GRIN2BGRIN1
SCHEMBL3395790 0.85 GRIN1 (1.00) GRIN2BGRIN1
SCHEMBL3772950 0.85 GRIN1 (1.00) GRIN2BGRIN1
SCHEMBL3390698 0.85 GRIN1 (1.00) GRIN2BGRIN1
SCHEMBL3392243 0.84 GRIN1 (1.00) GRIN2BGRIN1DRD1DRD2DRD4
SCHEMBL3394459 0.84 GRIN1 (1.00) GRIN2BGRIN1DRD1DRD2DRD4
SCHEMBL3392245 0.84 GRIN1 (1.00) GRIN2BGRIN1DRD1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) 2018-09-06 US disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
WO-2010122134-A1 NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS Westfälische Wilhelms Universität Münster (DE) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES GRIN1, GRIN2B, GRIN3B GRIN2B 2/4885GRIN1 1/4885DRD1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.